Related to Boehringer Ingelheim, Polyphor Partner on Macrocyclic Drug R&D

• Ablynx Wins €2M Milestone under Alzheimer Disease Deal with Boehringer Ingelheim
  
• Vitae Earns $14M from Boehringer Ingelheim with Start of Phase I Development
  
• Ablynx Receives €3M Milestone from BI and Starts Phase II Study with In-House Nanobody
  
• BI Taps MacroGenics in Multibillion-Dollar Deal for Antibody Development
  
• Lilly Pays BI €300M in Reciprocal Deal to Commercialize Joint Diabetes Pipeline
  
• Elan and BI Ink Deal for Development and Manufacture of Antibody Therapeutics
  
• MorphoSys and BI Sign Process Development and Manufacturing Deal for CLL mAb
  
• FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly
  
• Amylin Takes Lilly to Court over Diabetes Drug Development Deal with Boehringer Ingelheim
  
• Collaboration Gives Boehringer Ingelheim Rights to Zealand’s Type 2 Diabetes Candidate
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• Axxam and Polyphor Receive €3.1M for GLP-1 Receptor Diabetes Program
  
• BI Licenses ProBioGen’s GlymaxX Platform for Fucose-Free Antibody Production
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe
  
• BI and Nuevolution Leverage Chemetics Platform in Drug Discovery Collaboration
  
• Gilead Negotiates Worldwide License to BI’s Early Clinical Stage HIV Program
  
• Aveo Signs BI on as Production Partner for Clinical-Stage mAb
  
• ChemAxon Boosts Boehringer Ingelheim toward Next-Gen Cheminformatics
  
• OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
  
• BI and F-Star Ally to Develop Antibody-Based Therapeutics against Multiple Targets